GuidelineAmerican journal of respiratory and critical care medicine2014
An official American Thoracic Society Statement: pulmonary hypertension phenotypes.
Guideline in American journal of respiratory and critical care medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement.American journal of respiratory and critical care medicine · 2018Guideline
- Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report.American journal of respiratory and critical care medicine · 2017Guideline
- PVDOMICS: A Multi-Center Study to Improve Understanding of Pulmonary Vascular Disease Through Phenomics.Circulation research · 2017Trial
- Sotatercept Rescue Therapy for Acute Right Heart Failure in HIV-Associated PAH.Pulmonary circulation · 2026Article
- Article
- Hemodynamic Definitions, Phenotypes, Pathophysiology, and Evaluation of Pulmonary Hypertension Related to Left Heart Disease.Journal of cardiovascular development and disease · 2025Review
- Pharmacoepidemiology of combination pulmonary vasodilator therapy in critically ill infants.Cardiology in the young · 2025Article
- Emerging multimodality imaging techniques for the pulmonary circulation.The European respiratory journal · 2024Review
- Investigating the causal relationship between human blood metabolites and pulmonary hypertension: a two-sample Mendelian randomization study.Frontiers in cardiovascular medicine · 2024Article
- Circulating markers of inflammation and angiogenesis and clinical outcomes across subtypes of pulmonary arterial hypertension.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2023Observational
- Prime Time for Proteomics in Pulmonary Arterial Hypertension Risk Assessment?American journal of respiratory and critical care medicine · 2022Article
- Harnessing Big Data to Advance Treatment and Understanding of Pulmonary Hypertension.Circulation research · 2022Review
- Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension.The European respiratory journal · 2022Article
- Characterisation of paediatric pulmonary hypertensive vascular disease from the PPHNet Registry.The European respiratory journal · 2022Article
- Dominating Cause of Pulmonary Hypertension May Change Over Time-Diagnostic and Therapeutic Considerations in a Patient with Pulmonary Hypertension Due to Rheumatoid Arthritis with Lung Involvement.Diagnostics (Basel, Switzerland) · 2021Article
- Advances in the management of pulmonary arterial hypertension.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2021Review
- 'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension.Genes · 2020Review
- Treatment-related biomarkers in pulmonary hypertension patients on oral therapies.Respiratory research · 2020Article
- Specific O-GlcNAc modification at Ser-615 modulates eNOS function.Redox biology · 2020Article
- Pulmonary hypertension: From an orphan disease to a global epidemic.Global cardiology science & practice · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundCurrent classification of pulmonary hypertension (PH) is based on a relatively simple combination of patient characteristics and hemodynamics. This limits customization of treatment, and lacks the clarity of a more granular identification based on individual patient phenotypes. Rapid advances in mechanistic understanding of the disease, improved imaging methods, and innovative biomarkers now provide an opportunity to define PH phenotypes on the basis of biomarkers, advanced imaging, and pathobiology. This document organizes our current understanding of PH phenotypes and identifies gaps in our knowledge.
methodsA multidisciplinary committee with expertise in clinical care (pulmonary, cardiology, pediatrics, and pathology), clinical research, and/or basic science in the areas of PH identified important questions and reviewed and synthesized the literature.
resultsThis document describes selected PH phenotypes and serves as an initial platform to define additional relevant phenotypes as new knowledge is generated. The biggest gaps in our knowledge stem from the fact that our present understanding of PH phenotypes has not come from any particularly organized effort to identify such phenotypes, but rather from reinterpreting studies and reports that were designed and performed for other purposes.
conclusionsAccurate phenotyping of PH can be used in research studies to increase the homogeneity of study cohorts. Once the ability of the phenotypes to predict outcomes has been validated, phenotyping may also be useful for determining prognosis and guiding treatment. This important next step in PH patient care can optimally be addressed through a consortium of study sites with well-defined goals, tasks, and structure. Planning and support for this could include the National Institutes of Health and the U.S. Food and Drug Administration, with industry and foundation partnerships.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.